Claims for Patent: 10,464,890

Summary for Patent: 10,464,890

Title:	PGAM1 inhibitors and methods related thereto
Abstract:	In certain embodiments, the disclosure relates to methods of treating or preventing a PGAM1 mediated condition such as cancer or tumor growth comprising administering an effective amount of PGAM1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, head and neck cancer, and leukemia, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.
Inventor(s):	Chen; Jing (Atlanta, GA), Hitosugi; Taro (Decatur, GA), Kang; Sumin (Decatur, GA)
Assignee:	Emory University (Atlanta, GA)
Application Number:	15/847,670
Patent Claims:	1. A method of treating cancer comprising administering a pharmaceutical composition comprising a compound of Formula I to a subject diagnosed with or exhibiting symptoms of cancer, wherein the cancer is selected from leukemia, multiple myeloma, breast cancer, lung cancer, prostate cancer, liver cancer, colon cancer, head and neck cancer, the compound of Formula I is ##STR00003## prodrug, ester or salt thereof wherein: R.sup.1 is amino optionally substituted with one or more, the same or different, R.sup.9; R.sup.7 is hydroxy; R.sup.8 is hydroxy; R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6, are each individually and independently hydrogen, alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino (alkyl).sub.2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocycyl, wherein R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6, are optionally substituted with one or more, the same or different, R.sup.9; R.sup.9 is alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl).sub.2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R.sup.9 is optionally substituted with one or more, the same or different, R.sup.10, R.sup.10 is alkyl, halogen, nitro, cyano, hydroxy, amino, mercapto, formyl, carboxy, carbamoyl, alkoxy, alkylthio, alkylamino, (alkyl).sub.2amino, alkylsulfinyl, alkylsulfonyl, arylsulfonyl, carbocyclyl, aryl, or heterocyclyl, wherein R.sup.9 is optionally substituted with one or more, the same or different, R.sup.11; R.sup.11 is halogen, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, formyl, carboxy, carbamoyl, mercapto, sulfamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-meth ylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl, N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl, carbocyclyl, aryl, or heterocyclyl. 2. The method of claim 1, wherein R.sup.1 is amino and is substituted with an aryl ring, wherein the aryl ring is optionally substituted with one or more, the same or different R.sup.10. 3. The method of claim 1, wherein R.sup.1 is amino and is substituted with an aryl ring, wherein the aryl ring substituted in the para position with an alkyl, wherein the alkyl group is optionally substituted with one or more, the same or different R.sup.11. 4. The method of claim 1, wherein R.sup.1 is amino and is substituted with an aryl ring, wherein the aryl ring substituted in the para position with a methyl, wherein the methyl group is optionally substituted with one or more, the same or different R.sup.11. 5. The method of claim 1, wherein R.sup.1 is amino and is substituted with an aryl ring, wherein the aryl ring substituted in the para position with a methyl, wherein the methyl group is substituted with one or more, the same or different halogens. 6. The method of claim 1, wherein the pharmaceutical compositions is administered in combination with a second chemotherapeutic agent. 7. The method of claim 6, wherein the second chemotherapeutic agent is gefitinib, erlotinib, docetaxel, cis-platin, 5-fluorouracil, gemcitabine, tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin, vincristine, vinblastine, vindesine, vinorelbine taxol, taxotere, etoposide, teniposide, amsacrine, topotecan, camptothecin, bortezomib, anagrelide, tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene, fulvestrant, bicalutamide, flutamide, nilutamide, cyproterone, goserelin, leuprorelin, buserelin, megestrol, anastrozole, letrozole, vorazole, exemestane, finasteride, marimastat, trastuzumab, cetuximab, dasatinib, imatinib, bevacizumab, combretastatin, thalidomide, and/or lenalidomide or combinations thereof.

Details for Patent 10,464,890

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2031-10-14
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2031-10-14
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2031-10-14
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2031-10-14
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2031-10-14
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2031-10-14